251 related articles for article (PubMed ID: 19115972)
21. [Correlation, in previously treated HIV-1 positive patients, between hypersensitivity reaction to abacavir and the presence of the HLA-B*5701 allele].
Pérez Prior N; Rocher Milla A; Soler Company E; Flores Cid J; Sarria Chust B
Farm Hosp; 2009; 33(3):155-60. PubMed ID: 19712599
[TBL] [Abstract][Full Text] [Related]
22. A fluorescence-based sequence-specific primer PCR for the screening of HLA-B(*)57:01.
Giardina E; Stocchi L; Foti Cuzzola V; Zampatti S; Gambardella S; Patrizi MP; Bramanti P; Pirazzoli A; Novelli G
Electrophoresis; 2010 Oct; 31(21):3525-30. PubMed ID: 20925049
[TBL] [Abstract][Full Text] [Related]
23. A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndrome.
Martin AM; Krueger R; Almeida CA; Nolan D; Phillips E; Mallal S
Pharmacogenet Genomics; 2006 May; 16(5):353-7. PubMed ID: 16609367
[TBL] [Abstract][Full Text] [Related]
24. HLA-B*5701 screening for susceptibility to abacavir hypersensitivity.
Lucas A; Nolan D; Mallal S
J Antimicrob Chemother; 2007 Apr; 59(4):591-3. PubMed ID: 17317695
[TBL] [Abstract][Full Text] [Related]
25. Abacavir hypersensitivity.
Vandekerckhove L; Blot S; Vogelaers D
N Engl J Med; 2008 Jun; 358(23):2514-5; author reply 2515-6. PubMed ID: 18525052
[No Abstract] [Full Text] [Related]
26. Novel sensitive, specific and rapid pharmacogenomic test for the prediction of abacavir hypersensitivity reaction: HLA-B*57:01 detection by real-time PCR.
Dello Russo C; Lisi L; Lofaro A; Di Giambenedetto S; Federico B; Madeddu G; Salerno M; Mura MS; Pirazzoli A; de Luca A; Cauda R; Navarra P
Pharmacogenomics; 2011 Apr; 12(4):567-76. PubMed ID: 21521028
[TBL] [Abstract][Full Text] [Related]
27. Abacavir: pretreatment screening: warning. Encouraging method but uncertainties remain.
Prescrire Int; 2008 Dec; 17(98):239. PubMed ID: 19422151
[TBL] [Abstract][Full Text] [Related]
28. Current trends in screening across ethnicities for hypersensitivity to abacavir.
Rodriguez-Nóvoa S; Soriano V
Pharmacogenomics; 2008 Oct; 9(10):1531-41. PubMed ID: 18855539
[TBL] [Abstract][Full Text] [Related]
29. External quality assessment of HLA-B*5701 reporting: an international multicentre survey.
Hammond E; Almeida CA; Mamotte C; Nolan D; Phillips E; Schollaardt TA; Gill MJ; Angel JB; Neurath D; Li J; Giulivi T; McIntyre C; Koultchitski G; Wong B; Reis M; Rachlis A; Cole DE; Chew CB; Neifer S; Lalonde R; Roger M; Jeanneau A; Mallal S
Antivir Ther; 2007; 12(7):1027-32. PubMed ID: 18018760
[TBL] [Abstract][Full Text] [Related]
30. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.
Mallal S; Nolan D; Witt C; Masel G; Martin AM; Moore C; Sayer D; Castley A; Mamotte C; Maxwell D; James I; Christiansen FT
Lancet; 2002 Mar; 359(9308):727-32. PubMed ID: 11888582
[TBL] [Abstract][Full Text] [Related]
31. Genetic screening to prevent abacavir hypersensitivity reaction: are we there yet?
Phillips EJ
Clin Infect Dis; 2006 Jul; 43(1):103-5. PubMed ID: 16758425
[No Abstract] [Full Text] [Related]
32. HLA-B*5701 genetic screening prior to abacavir prescription in Georgia.
Dvali N; Chkhartishvili N; Sharvadze L; Karchava M; Tsertsvadze T
Georgian Med News; 2010 Dec; (189):16-20. PubMed ID: 21252404
[TBL] [Abstract][Full Text] [Related]
33. HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects.
Small CB; Margolis DA; Shaefer MS; Ross LL
BMC Infect Dis; 2017 Apr; 17(1):256. PubMed ID: 28399804
[TBL] [Abstract][Full Text] [Related]
34. Abacavir hypersensitivity reaction.
AIDS Patient Care STDS; 2002 May; 16(5):242. PubMed ID: 12058699
[No Abstract] [Full Text] [Related]
35. Value of the HLA-B*5701 allele to predict abacavir hypersensitivity in Spaniards.
Rodríguez-Nóvoa S; García-Gascó P; Blanco F; González-Pardo G; Castellares C; Moreno V; Jiménez-Nácher I; González-Lahoz J; Soriano V
AIDS Res Hum Retroviruses; 2007 Nov; 23(11):1374-6. PubMed ID: 18184080
[TBL] [Abstract][Full Text] [Related]
36. HLA-B*5701 frequency in Chilean HIV-infected patients and in general population.
Poggi H; Vera A; Lagos M; Solari S; Rodríguez P L; Pérez CM
Braz J Infect Dis; 2010; 14(5):510-2. PubMed ID: 21221482
[TBL] [Abstract][Full Text] [Related]
37. HLA-B*5701 genetic screening among HIV-1 infected patients in Hong Kong: is this a practical approach in Han-Chinese?
To SW; Chen JH; Wong KH; Chan KC; Tsang OT; Yam WC
Int J STD AIDS; 2013 Jan; 24(1):50-2. PubMed ID: 23512513
[TBL] [Abstract][Full Text] [Related]
38. Are mutations in HIV type-1 reverse transcriptase 245 codon predictive of abacavir hypersensitivity reaction?
Bracciale L; Santangelo R; Fanti I; Prosperi M; Colafigli M; Di Giambenedetto S; Marchetti S; Di Franco A; Cauda R; De Luca A
Antivir Ther; 2009; 14(1):99-101. PubMed ID: 19320242
[TBL] [Abstract][Full Text] [Related]
39. Absence of human leukocyte antigen-B*57:01 amongst patients on antiretroviral therapy in Nigeria: Implications for use of abacavir.
Agbaji OO; Akanbi MO; Otoh I; Agaba PA; Akinsola R; Okolie V; Ugoagwu PO; Babadoko AA; Adediran A; Finomo FO; Abah JO; Muktar HM; Akanmu AS
Niger Postgrad Med J; 2019; 26(4):195-198. PubMed ID: 31621657
[TBL] [Abstract][Full Text] [Related]
40. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir.
Hetherington S; Hughes AR; Mosteller M; Shortino D; Baker KL; Spreen W; Lai E; Davies K; Handley A; Dow DJ; Fling ME; Stocum M; Bowman C; Thurmond LM; Roses AD
Lancet; 2002 Mar; 359(9312):1121-2. PubMed ID: 11943262
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
